Skip to main content

Advertisement

Table 1 Differentially expressed proteins identified by 2-DE

From: Complementary serum proteomic analysis of autoimmune hepatitis in mice and patients

Spot no. Protein Gene name Function Accession Theoretical Mr/pIa Scoreb No. of pep.c Expression level (AIH/Control) d iTRAQ validation (116/114)e
1 serum amyloid A2 SAA2 acute phase reactant gi6755394 13613.5/6.41 122 2 ↑6.56 ± 0.2 N/Af
2 serum amyloid A1 SAA1 acute phase reactant gi404753 13691.5/6.5 45 2 ↑14.72 ± 2.1 N/A
3 alpha-fetoprotein AFP estrogens, fatty acids and metals binding gi191765 47194.9/5.47 172 7 ↑3.00 ± 0.9 N/A
4 complement C3 C3 activation immune gi126518317 187904/6.31 44 3 ↑2.41 ± 0.06 2.19
5 glutathione peroxidase GPX4 oxidative damage protecting calcium ion binding gi2673845 22290.59/6.74 54 3 ↑4.16 ± 0.18 N/A
6 fumarylacetoacetase FAH enzyme regulator activity; protein binding gi253320 46416/6.56 43 4 ↑12.4 ± 0.78 N/A
7 alpha-2-macroglobulin A2M activation immune gi110347469 167144/6.17 41 3 ↑1.98 ± 0.23 1.61
8 interleukin 17 F IL17F actin/ vitamin D binding gi22003916 17008.8/9.05 40 2 ↓8.3 ± 1.11 N/A
9 vitaminD-binding protein precursor GC vitamin transporter activity gi51172612 53565/5.39 56 3 ↓2.08 ± 0.2 N/A
  1. aTheoretical molecular weight (kDa) and pI from the ExPASy database.
  2. bProbability-based Mascot scores.
  3. cNumber of unique peptides identified by MS/MS.
  4. dAverage expression level of altered proteins by 2-DE and MS from three independent analyses (mean ± SD) (↑,increased; ↓, decreased).
  5. eThe differential expression of proteins in serum from AIH patients and controls was validated by iTRAQ (average of the two experiments, control: 114; AIH: 116).
  6. fN/A, Not analyzed by iTRAQ.